28
Oct
2025

Shanghai Henlius Biotech, Inc.

Exhibitor at CPHI Frankfurt 2025 stand 3.1A92, Finished Dosage Formulations
About Us

Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable, and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases, and ophthalmic diseases. Up to date, 6 products have been launched in China, 3 have been approved for marketing in overseas markets, 24 indications are approved worldwide, and 3 marketing applications have been accepted for review in China and the EU, respectively. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of.....

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • CN
  • 2019
    On CPHI since
  • 2
    Certificates
  • 1000 - 4999
    Employees
Company types
Biopharmaceutical company
Generics/Biosimilars Manufacturer
Primary activities
Biopharmaceutical
Pharmaceutical Company (innovator finished products)
View company profile
Contact info
  • +15221054507
  • Website
  • 12/F, B8 Building, No.188 Yizhou Rd, Xuhui District, 200233, Shanghai, China
Show contact info Hide contact info
Event information
CPHI Frankfurt 2025
  • 28 Oct 2025 - 30 Oct 2025
  • Messe, Frankfurt
  • Visit us at stand 3.1A92, Finished Dosage Formulations

Products Featured at CPHI Frankfurt 2025

  • HANBEITAI (Bevacizumab Injection)

    Product HANBEITAI (Bevacizumab Injection)

    HANBEITAI (generic name: bevacizumab), the fourth product independently developed by Henlius, received marketing approval from the National Medical Products Administration (NMPA) in November 2021, and its commercialization in Chinese mainland is handled by the company’s in-house team. As of now, HANBEI...
  • HANDAYUAN (Adalimumab Injection)

    Product HANDAYUAN (Adalimumab Injection)

    Our first product indicated for the treatment of autoimmune diseases. HANDAYUAN (adalimumab injection) was approved by the NMPA in December 2020. It is indicated for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, uveitis, polyarticular juvenile idiopathic arthritis,  pediatric plaque ...
  • HANLIKANG (Rituximab Injection)

    Product HANLIKANG (Rituximab Injection)

    HANLIKANG (rituximab injection) is the company's first proprietary product. It is the first-ever China-manufactured biosimilar approved by the NMPA in accordance with the Technical Guideline for the Development and Evaluation of Biosimilars (Tentative) issued in 2015. As of now, HANLIKANG has bee...
  • HANQUYOU（trastuzumab)

    Product HANQUYOU（trastuzumab)

    HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac® in Europe) was successfully launched in the U.S., China and Europe, becoming the Chinese mAb biosimilar entering the U.S., the EU and China market. It is indicated for the treatment of HER2 positive early breast cancer, metastatic bre...
  • HANSIZHUANG (Serplulimab Injection)

    Product HANSIZHUANG (Serplulimab Injection)

    HANSIZHUANG (recombinant humanized anti-PD-1 monoclonal antibody injection, generic name: serplulimab injection) is the first anti-PD-1 mAb for the first-line treatment of SCLC and has been approved in China and Indonesia. Up to date, 4 indications are approved for marketing, 2 marketing applications a...

Shanghai Henlius Biotech, Inc. Resources (1)